{"id":"NCT00728481","sponsor":"Mayo Clinic","briefTitle":"The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis","officialTitle":"The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-05","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2008-08-05","resultsPosted":"2012-12-06","lastUpdate":"2016-01-14"},"enrollment":51,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Esophagitis","Gastroesophageal Reflux Disease","EE","GERD"],"interventions":[{"type":"DRUG","name":"Esomeprazole","otherNames":["Nexium"]},{"type":"DRUG","name":"Budesonide","otherNames":["Pulmicort"]}],"arms":[{"label":"Esomeprazole","type":"ACTIVE_COMPARATOR"},{"label":"Budesonide","type":"ACTIVE_COMPARATOR"}],"summary":"The primary aim of this study was to determine the proportion of patients with esophageal eosinophilic infiltration that have objective (measurable) evidence of gastroesophageal reflux disease (GERD).\n\nThis study was also done to see if patients that have eosinophilic esophagitis (EE) and GERD would receive relief from taking the medication Nexium or a steroid called Pulmicort.\n\nThe study also evaluated the accuracy of pH monitoring (acid exposure) within the esophagus as a predictor of endoscopic, histological and symptomatic response in patients with EE.","primaryOutcome":{"measure":"Histological Response to Treatment","timeFrame":"Baseline, 6 months","effectByArm":[{"arm":"Esomeprazole","deltaMin":11,"sd":null},{"arm":"Budesonide","deltaMin":16,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"1.00"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["22111863"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Hives"]}}